Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lactobacillus Reuteri Strain Combination in Children Treated With PPI
Sponsor: University of Bari
Summary
Probiotics might be of help in preventing dysbiosis and emergence of SIBO. Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475; the first have extensive data supporting its use in gastric infections (18) however, it lacks the anti-inflammatory properties that have been provided by L. Reuteri DSM ATCC PTA 6475 that has excellent acid resistance and has strong anti-inflammatory properties (19); for these reasons, Gastrus is the best candidate for this indication.
Official title: Lactobacillus Reuteri Strain Combination (Strains DSM 17938 and ATCC PTA 6475) in Children Treated With Proton Pump Inhibitors
Key Details
Gender
All
Age Range
12 Months - 14 Years
Study Type
INTERVENTIONAL
Enrollment
172
Start Date
2020-03-04
Completion Date
2025-12-31
Last Updated
2024-12-05
Healthy Volunteers
No
Interventions
Gastrus
Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475. Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus.
Placebo
placebo has an identical preparation to Gastrus
Locations (1)
Fernanda
Bari, Italy